Evidence map›Paper›PMID 32556862›Full record

ArticleJournal of neuro-oncology2020

Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.

Erin E Crotty, Sarah E S Leary, J Russell Geyer, James M Olson, Nathan E Millard, Aimee A Sato, Ralph P Ermoian, Bonnie L Cole, Christina M Lockwood, Vera A Paulson and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Bevacizumab in Pediatric Neuro-Oncology.Current oncology (Toronto, Ont.) · 2025
    Review
  4. Review
  5. Epigenetics to clinicopathological features: a bibliometric analysis of H3 G34-mutant diffuse hemispheric glioma literature.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Review
  6. Article
  7. Review
  8. Radiotherapy and radio-sensitization in H3CNS neuroscience & therapeutics · 2023
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022
    Article
  14. Essential Management of Pediatric Brain Tumors.Children (Basel, Switzerland) · 2022
    Review
  15. Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Erin E CrottyDivision of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, 4800 Sand Point Way NE, M/S MB.8.501, PO Box 5371, Seattle, WA, 98105, USA.
Sarah E S LearyDivision of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, 4800 Sand Point Way NE, M/S MB.8.501, PO Box 5371, Seattle, WA, 98105, USA.
J Russell GeyerDivision of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, 4800 Sand Point Way NE, M/S MB.8.501, PO Box 5371, Seattle, WA, 98105, USA.
James M OlsonDivision of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, 4800 Sand Point Way NE, M/S MB.8.501, PO Box 5371, Seattle, WA, 98105, USA.
Nathan E MillardDivision of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, 4800 Sand Point Way NE, M/S MB.8.501, PO Box 5371, Seattle, WA, 98105, USA.
Aimee A SatoDivision of Pediatric Neurology, Department of Neurology, University of Washington, Seattle, WA, USA.
Ralph P ErmoianDepartment of Radiation Oncology, University of Washington, Seattle, WA, USA.
Bonnie L ColeDepartment of Laboratories, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Christina M LockwoodDepartment of Laboratory Medicine, Genetics and Solid Tumor Diagnostics Laboratory, University of Washington and Seattle Children's Hospital, Seattle, WA, USA.
Vera A PaulsonDepartment of Laboratory Medicine, Genetics and Solid Tumor Diagnostics Laboratory, University of Washington and Seattle Children's Hospital, Seattle, WA, USA.
Samuel R BrowdDivision of Neurosurgery, Department of Neurological Surgery, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Richard G EllenbogenDivision of Neurosurgery, Department of Neurological Surgery, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Jason S HauptmanDivision of Neurosurgery, Department of Neurological Surgery, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Amy LeeDivision of Neurosurgery, Department of Neurological Surgery, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Jeffrey G OjemannDivision of Neurosurgery, Department of Neurological Surgery, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Nicholas A VitanzaDivision of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, 4800 Sand Point Way NE, M/S MB.8.501, PO Box 5371, Seattle, WA, 98105, USA. Nicholas.Vitanza@seattlechildrens.org.ORCID http://orcid.org/0000-0002-3966-4985
Seattle Children's Hospital · USUniversity of Washington · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBeyond focal radiation, there is no consensus standard therapy for pediatric high-grade glioma (pHGG) and outcomes remain dismal. We describe the largest molecularly-characterized cohort of children with pHGG treated with a 3-drug maintenance regimen of temozolomide, irinotecan, and bevacizumab (TIB) following radiation.

methodsWe retrospectively reviewed 36 pediatric patients treated with TIB at Seattle Children's Hospital from 2009 to 2018 and analyzed survival using the Kaplan-Meier method. Molecular profiling was performed by targeted DNA sequencing and toxicities, steroid use, and palliative care utilization were evaluated.

resultsMedian age at diagnosis was 10.9 years (18 months-18 years). Genetic alterations were detected in 26 genes and aligned with recognized molecular subgroups including H3 K27M-mutant (12), H3F3A G34-mutant (2), IDH-mutant (4), and hypermutator profiles (4). Fifteen patients (42%) completed 12 planned cycles of maintenance. Side effects associated with chemotherapy delays or modifications included thrombocytopenia (28%) and nausea/vomiting (19%), with temozolomide dosing most frequently modified. Median event-free survival (EFS) and overall survival (OS) was 16.2 and 20.1 months, with shorter survival seen in DIPG (9.3 and 13.3 months, respectively). Survival at 1, 2, and 5 years was 80%, 10% and 0% for DIPG and 85%, 38%, and 16% for other pHGG.

conclusionOur single-center experience demonstrates tolerability of this 3-drug regimen, with prolonged survival in DIPG compared to historical single-agent temozolomide. pHGG survival was comparable to analogous 3-drug regimens and superior to historical agents; however, cure was rare. Children with pHGG remain excellent candidates for the study of novel therapeutics combined with standard therapy.

Indexed as

AdolescentAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBrain Stem NeoplasmsChildChild, PreschoolDiffuse Intrinsic Pontine GliomaFemaleFollow-Up StudiesGliomaHumansInfantIrinotecanMaleNeoplasm GradingRetrospective StudiesBevacizumabIrinotecanTemozolomideBevacizumabDiffuse intrinsic pontine gliomaIrinotecanPediatric high-grade gliomaTemozolomide

Identifiers

PMID32556862
OpenAlexW3036981827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.